Moody Aldrich Partners’s BridgeBio Pharma BBIO Stock Holding History

Moody Aldrich Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$257K	Sell	3,455 -72,493	-95%	-$5.08M	0.05%	165
2026 Q1	$5.64M	Sell	75,948 -55,236	-42%	-$4M	1.02%	33
2025 Q4	$10M	Buy	131,184 +59,604	+83%	+$3.91M	1.87%	4
2025 Q3	$3.72M	Sell	71,580 -23,855	-25%	-$1.16M	0.71%	70
2025 Q2	$4.12M	Sell	95,435 -1,480	-2%	-$53.8K	0.8%	61
2025 Q1	$3.35M	Sell	96,915 -2,769	-3%	-$93.4K	0.7%	60
2024 Q4	$2.74M	Sell	99,684 -23,825	-19%	-$616K	0.51%	78
2024 Q3	$3.14M	Sell	123,509 -2,320	-2%	-$60.9K	0.57%	76
2024 Q2	$3.19M	Sell	125,829 -23,393	-16%	-$640K	0.62%	77
2024 Q1	$4.61M	Buy	149,222 +24,238	+19%	+$824K	0.78%	55
2023 Q4	$5.05M	Sell	124,984 -12,528	-9%	-$376K	0.91%	45
2023 Q3	$3.63M	Buy	137,512 +57,639	+72%	+$1.64M	0.69%	63
2023 Q2	$1.37M	Sell	79,873 -64,980	-45%	-$978K	0.27%	105
2023 Q1	$2.4M	Buy	+144,853	New	+$1.69M	0.48%	80

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Moody Aldrich Partners's BBIO Position: Q2 2026 in Review

Moody Aldrich Partners reduced its BridgeBio Pharma (BBIO) stake by 95% in Q2 2026, selling an estimated $5.08M and leaving 3,455 shares worth $257K. The position accounts for 0.05% of the portfolio, ranked #165.

Moody Aldrich Partners first reported a position in BBIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $10M in Q4 2025. 64 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Moody Aldrich Partners held 3,455 shares of BridgeBio Pharma worth $257K as of Q2 2026.
Moody Aldrich Partners sold 72,493 BridgeBio Pharma shares in Q2 2026, an estimated $5.08M.
BridgeBio Pharma made up 0.05% of Moody Aldrich Partners's portfolio in Q2 2026, its #165 holding.
Moody Aldrich Partners first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 14 quarters since.
Moody Aldrich Partners's BridgeBio Pharma position peaked at $10M in Q4 2025.
64 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.